2/26
02:11 pm
vir
Vir Biotechnology (VIR) had its "outperform" rating reaffirmed by Leerink Partners.
Low
Report
Vir Biotechnology (VIR) had its "outperform" rating reaffirmed by Leerink Partners.
2/25
11:12 am
vir
Rating for VIR
Medium
Report
Rating for VIR
2/25
11:12 am
vir
Rating for VIR
Medium
Report
Rating for VIR
2/24
03:08 pm
vir
Vir Biotechnology (VIR) had its "overweight" rating reaffirmed by Barclays PLC.
Low
Report
Vir Biotechnology (VIR) had its "overweight" rating reaffirmed by Barclays PLC.
2/24
12:40 pm
vir
Rating for VIR
Low
Report
Rating for VIR
2/24
12:40 pm
vir
Rating for VIR
Low
Report
Rating for VIR
2/24
10:29 am
vir
Rating for VIR
Medium
Report
Rating for VIR
2/24
07:18 am
vir
Vir Biotechnology (NASDAQ:VIR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
High
Report
Vir Biotechnology (NASDAQ:VIR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
2/24
07:18 am
vir
Vir Biotechnology (NASDAQ:VIR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
High
Report
Vir Biotechnology (NASDAQ:VIR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
2/24
07:01 am
vir
Vir Biotechnology (NASDAQ:VIR) was upgraded by analysts at Raymond James Financial, Inc. from an "outperform" rating to a "strong-buy" rating.
High
Report
Vir Biotechnology (NASDAQ:VIR) was upgraded by analysts at Raymond James Financial, Inc. from an "outperform" rating to a "strong-buy" rating.
2/24
06:09 am
vir
Vir Biotechnology upgraded to Strong Buy from Outperform at Raymond James
High
Report
Vir Biotechnology upgraded to Strong Buy from Outperform at Raymond James
2/24
06:09 am
vir
Vir Biotechnology upgraded to Strong Buy from Outperform at Raymond James
High
Report
Vir Biotechnology upgraded to Strong Buy from Outperform at Raymond James
2/24
05:55 am
vir
Rating for VIR
High
Report
Rating for VIR
2/24
05:55 am
vir
Rating for VIR
High
Report
Rating for VIR
2/9
08:04 am
vir
Vir Biotechnology (NASDAQ:VIR) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.
Low
Report
Vir Biotechnology (NASDAQ:VIR) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.
2/9
05:58 am
vir
Rating for VIR
Low
Report
Rating for VIR
2/9
05:58 am
vir
Rating for VIR
Low
Report
Rating for VIR
2/4
06:09 am
vir
Vir Biotechnology (NASDAQ:VIR) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
Vir Biotechnology (NASDAQ:VIR) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
12/30
08:42 am
vir
Vir Biotechnology (NASDAQ:VIR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Low
Report
Vir Biotechnology (NASDAQ:VIR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.